Psoriatic Arthritis Video Perspectives

In this video series, Joerg Ermann, MD, from the division of rheumatology, inflammation and immunity at Brigham and Women’s Hospital, discussed:

• Recent developments in psoriatic arthritis, like inhibition of IL-23 and IL-17A and data from head-to-head drug trials;
• “Contradictory results” regarding combination therapy in psoriatic arthritis;
• Therapeutic targets under investigation, such as JAKs that target different specificities and using small molecules to inhibit different pathways;
• “An increasingly complex field:” identifying which domain is the most prominent and which domain has the most impact on the person’s life to choose the most effective therapy for the individual patient with psoriatic disease;
• Racial and ethnic disparities in disease activity and clinical outcomes in PsA;
• The importance of educating medical students and trainees on the differences in skin manifestations in patients with skin of color and the need to include a wider range of ethnic groups and countries in genetic and clinical PsA studies; and
• The need to understand the factors underlying progression from psoriasis to psoriatic arthritis and the need for personalized medicine.